Lv41
620 积分 2021-08-16 加入
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
2小时前
待确认
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK
5个月前
已完结
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
8个月前
已完结
Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome
9个月前
已完结
Janus kinase inhibition in juvenile idiopathic arthritis
9个月前
已完结
Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis
9个月前
已完结
Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis
9个月前
已完结
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
9个月前
已完结
Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases
9个月前
已完结
Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?
9个月前
已完结
皖公网安备34019202002308
